OKYO Pharma Says OK-101 Achieves Statistical Significance For Multiple Signs And Symptoms Of Dry Eye Disease Including Ocular Pain Relief In Its First-in-Human Phase 2 Trial Of OK-101

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!